Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly, Food and Drug Administration
Eli Lilly's shortage of diabetes and obesity drugs is over, halting competition with knock-offs
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have been producing copycat versions of the in-demand treatments.
Eli Lilly’s weight-loss drug no longer in shortage, FDA says
The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug Administration announced Wednesday.
Eli Lilly’s Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers.
Eli Lilly’s blockbuster obesity and diabetes drugs Zepbound and Mounjaro are no longer in shortage, according to the Food and Drug Administration.It’s a sign that pharmaceutical firm Lilly is making strides to improve the supply issues that have plagued the sector.
Mounjaro, Zepbound shortage eases as supplies of weight loss drug rebound
Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit cheaper copycat versions.
What end of Eli Lilly's weight-loss drug shortage means for the competition
The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 diabetes drug Mounjaro, implying the company can now supply enough doses to meet current demand.
Eli Lilly's Mounjaro, Zepbound removed from FDA's shortage list
GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list. Senior Health Reporter Anjalee Khemlani reports more on the story and what it means for competitors,
Mounjaro and Zepbound no longer in shortage
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been resolved. Tirzepatide, the active ingredient in the diabetes and
Eli Lilly weight-loss drug shortage ends, shaking up telehealth
Compounded versions of popular weight-loss drugs attracted telehealth companies that marketed services to connect patients with healthcare providers.
Lilly's weight-loss drug removed from FDA's shortage list
Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug Administration's website showed on Wednesday.
Eli Lilly’s Weight-Loss, Diabetes Drug Shortages Are Over, FDA Says
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making custom-made versions.
FDA makes end of Zepbound, Mounjaro shortage official
Removal of Lilly’s in-demand drugs from the FDA’s shortage list ramps up pressure on the companies selling compounded counterparts.
GlobalData on MSN
1d
NHS proposes phased launch for Eli Lilly’s Mounjaro
The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...
FiercePharma
2d
NHS England proposes phased rollout for Eli Lilly's star obesity drug
While Mounjaro was cleared for use in England last year, Lilly put its launch on hold until its pre-filled injection device, ...
1d
England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
NHS England plans a phased rollout of tirzepatide to treat severe obesity, with early trials showing significant weight loss.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Ex-Lions quarterback dies
US launches airstrikes
Registration deadlines
Tucker faces defamation suit
Yellow jackets swarm in NC
Warns of potential threats
Mich. double voting incident
Judge denies request
Bills Hall of Famer dies
Bans pagers, walkie-talkies
Paterson, stepson attacked
Stellantis sues UAW
Glover cancels tour dates
Hurricane forecast for FL
US $157M aid for Lebanon
To stop linking to NZ news?
Won’t renew CHNV parole
Congo starts mpox vaccines
SCOTUS allows EPA rules
To add Hyundai EVs
Sixth Player of the Year
To resume talks with union
US, SK troop-funding deal
To weigh TX death row case
Read seeks to delay lawsuit
To lead LA police force
ULA launches Vulcan rocket
Bird flu vaccine supply boost
Catches fire while landing
Reaches China Open final
Trump returns to Butler
US wiretap systems targeted
Related topics
Food and Drug Administration
Zepbound
NHS
Feedback